Sort by

Send to

Choose Destination

Search results

Items: 6


Inducible silencing of protein kinase D3 inhibits secretion of tumor-promoting factors in prostate cancer.

LaValle CR, Zhang L, Xu S, Eiseman JL, Wang QJ.

Mol Cancer Ther. 2012 Jul;11(7):1389-99. doi: 10.1158/1535-7163.MCT-11-0887.


Design, Synthesis, and Biological Evaluation of PKD Inhibitors.

George KM, Frantz MC, Bravo-Altamirano K, Lavalle CR, Tandon M, Leimgruber S, Sharlow ER, Lazo JS, Wang QJ, Wipf P.

Pharmaceutics. 2011;3(2):186-228. doi: 10.3390/pharmaceutics3020186.


Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D.

Bravo-Altamirano K, George KM, Frantz MC, Lavalle CR, Tandon M, Leimgruber S, Sharlow ER, Lazo JS, Wang QJ, Wipf P.

ACS Med Chem Lett. 2011 Feb 14;2(2):154-159.


Protein kinase D as a potential new target for cancer therapy.

LaValle CR, George KM, Sharlow ER, Lazo JS, Wipf P, Wang QJ.

Biochim Biophys Acta. 2010 Dec;1806(2):183-92. doi: 10.1016/j.bbcan.2010.05.003. Review.


Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility.

Lavalle CR, Bravo-Altamirano K, Giridhar KV, Chen J, Sharlow E, Lazo JS, Wipf P, Wang QJ.

BMC Chem Biol. 2010 May 5;10:5. doi: 10.1186/1472-6769-10-5.


Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone.

Sharlow ER, Giridhar KV, LaValle CR, Chen J, Leimgruber S, Barrett R, Bravo-Altamirano K, Wipf P, Lazo JS, Wang QJ.

J Biol Chem. 2008 Nov 28;283(48):33516-26. doi: 10.1074/jbc.M805358200.

Items per page

Supplemental Content

Loading ...
Support Center